Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): An updated review

References

• Ahmad, N., Adhami, V. M., Gupta, S., Cheng, P. Y. and Mukhtar, H. (2002). Role of the retinoblastoma (pRb)-E2F/DP pathway in cancer chemopreventive effects of green tea polyphenol epigallocatechin-3-gallate. Arch. Biochem. Biophys. 398:125–131.
   PubMed Web of Science ®Google Scholar
• Ahuja, N., Sharma, A. R. and Baylin, S. B. (2016). Epigenetic therapeutics: a new weapon in the war against cancer. Annu. Rev. Med. 67:73–89.
   PubMed Web of Science ®Google Scholar
• Ajani, J. A., Song, S., Hochster, H. S. and Steinberg, I. B. (2015). Cancer stem cells: the promise and the potential. Semin. Oncol. 42:S3–S17.
   PubMed Web of Science ®Google Scholar
• Albrecht, D. S., Clubbs, E. A., Ferruzzi, M. and Bomser, J. A. (2008). Epigallocatechin-3-gallate (EGCG) inhibits PC-3 prostate cancer cell proliferation via MEK-independent ERK1/2 activation. Chem.-Biol. Interact. 171:89–95.
   PubMed Web of Science ®Google Scholar
• Baatout, S., Jacquet, P., Derradji, H., Ooms, D., Michaux, A. and Mergeay, M. (2004). Study of the combined effect of X-irradiation and epigallocatechin-gallate (a tea component) on the growth inhibition and induction of apoptosis in human cancer cell lines. Oncol. Rep. 12:159–167.
   PubMed Web of Science ®Google Scholar
• Bai, L. C. and Wang, S. M. (2014). Targeting apoptosis pathways for new cancer therapeutics. Annu. Rev. Med. 65:139–155.
   PubMed Web of Science ®Google Scholar
• Balasubramanian, S., Adhikary, G. and Eckert, R. L. (2010). The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival. Carcinogenesis 31:496–503.
   PubMed Web of Science ®Google Scholar
• Balkwill, F. (2004). Cancer and the chemokine network. Nat. Rev. Cancer. 4:540–550.
   PubMed Web of Science ®Google Scholar
• Basu, A. and Haldar, S. (2009). Combinatorial effect of epigallocatechin-3-gallate and TRAIL on pancreatic cancer cell death. Int. J. Oncol. 34:281–286.
   PubMed Web of Science ®Google Scholar
• Belguise, K., Guo, S. Q. and Sonenshein, G. E. (2007). Activation of FOXO3a by the green tea polyphenol epigallocatechin-3-gallate induces estrogen receptor alpha expression reversing invasive phenotype of breast cancer cells. Cancer Res. 67:5763–5770.
   PubMed Web of Science ®Google Scholar
• Bhagwat, A. S. and Vakoc, C. R. (2015). Targeting transcription factors in cancer. Trends Cancer 1:53–65.
   PubMed Web of Science ®Google Scholar
• Bhatia, N., Agarwal, C. and Agarwal, R. (2001). Differential responses of skin cancer-chemopreventive agents silibinin, quercetin and epigallocatechin 3-gallate on mitogenic signaling and cell cycle regulators in human epidermoid carcinoma A431 cells. Nutr. Cancer 39:292–299.
   PubMed Web of Science ®Google Scholar
• Bimonte, S., Leongito, M., Barbieri, A., Del Vecchio, V., Barbieri, M., Albino, V., Piccirillo, M., Amore, A., Di Giacomo, R., Nasto, A., Granata, V., Petrillo, A., Arra, C. and Izzo, F. (2015). Inhibitory effect of (-)-epigallocatechin-3-gallate and bleomycin on human pancreatic cancer MiaPaca-2 cell growth. Infect. Agents Cancer 10:22.
   PubMed Web of Science ®Google Scholar
• Bose, M., Lambert, J. D., Ju, J., Reuhl, K. R., Shapses, S. A. and Yang, C. S. (2008). The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome and fatty liver disease in high-fat-fed mice. J. Nutr. 138:1677–1683.
   PubMed Web of Science ®Google Scholar
• Braicu, C., Gherman, C. D., Irimie, A. and Berindan-Neagoe, I. (2013). Epigallocatechin-3-gallate (EGCG) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cells. J. Nanosci. Nanotechno. 13:632–637.
   PubMed Web of Science ®Google Scholar
• Cai, Y. Z., Mei, S., Jie, X., Luo, Q. and Corke, H. (2006). Structure-radical scavenging activity relationships of phenolic compounds from traditional Chinese medicinal plants. Life Sci. 78:2872–2888.
   PubMed Web of Science ®Google Scholar
• Chalah, A. and Khosravi-Far, R. (2008). The mitochondrial death pathway. Adv. Exp. Med. Biol. 615:25–45.
   PubMed Web of Science ®Google Scholar
• Chen, D., Pamu, S., Cui, Q. Z., Chan, T. H. and Dou, Q. P. (2012). Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells. Bioorgan. Med. Chem. 20:3031–3037.
   PubMed Web of Science ®Google Scholar
• Chen, J. C., Zeng, F. H., Forrester, S. J., Eguchi, S., Zhang, M. Z. and Harris, R. C. (2016). Expression and function of the epidermal growth factor receptor in physiology and disease. Physiol. Rev. 96:1025–1069.
   PubMed Web of Science ®Google Scholar
• Chen, P. N., Chu, S. C., Kuo, W. H., Chou, M. Y., Lin, J. K. and Hsieh, Y. S. (2011). Epigallocatechin-3 gallate inhibits invasion, epithelial-mesenchymal transition, and tumor growth in oral cancer cells. J. Agric. Food Chem. 59:3836–3844.
   PubMed Web of Science ®Google Scholar
• Chen, Q. S., Guo, Z. M. and Zhao, J. W. (2008). Identification of green tea's (Camellia sinensis (L.)) quality level according to measurement of main catechins and caffeine contents by HPLC and support vector classification pattern recognition. J. Pharmaceut. Biomed. 48:1321–1325.
   PubMed Web of Science ®Google Scholar
• Cheng, C. W., Shieh, P. C., Lin, Y. C., Chen, Y. J., Lin, Y. H., Kuo, D. H., Liu, J. Y., Kao, J. Y., Kao, M. C. and Way, T. D. (2010). Indoleamine 2,3-dioxygenase, an immunomodulatory protein, is suppressed by (-)-epigallocatechin-3-gallate via blocking of gamma-interferon-induced JAK-PKC-delta-STAT1 signaling in human oral cancer cells. J. Agric. Food Chem. 58:887–894.
   PubMed Web of Science ®Google Scholar
• Chiou, Y. S., Sang, S. M., Cheng, K. H., Ho, C. T., Wang, Y. J. and Pan, M. H. (2013). Peracetylated (-)-epigallocatechin-3-gallate (AcEGCG) potently prevents skin carcinogenesis by suppressing the PKD1-dependent signaling pathway in CD34(+) skin stem cells and skin tumors. Carcinogenesis 34:1315–1322.
   PubMed Web of Science ®Google Scholar
• Cho, S. G. and Choi, E. J. (2002). Apoptotic signaling pathways: caspases and stress-activated protein kinases. J. Biochem. Mol. Biol. 35:24–27.
   PubMedGoogle Scholar
• Chuu, C. P., Chen, R. Y., Kokontis, J. M., Hiipakka, R. A. and Liao, S. (2009). Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells. Cancer Lett. 275:86–92.
   PubMed Web of Science ®Google Scholar
• Cromie, M. M. and Gao, W. M. (2015). Epigallocatechin-3-gallate enhances the therapeutic effects of leptomycin B on human lung cancer A549 cells. Oxid. Med. Cell Longev. 2015:217304, doi:10.1155/2015/217304.
   PubMed Web of Science ®Google Scholar
• D'Angelo, L., Piazzi, G., Pacilli, A., Prossomariti, A., Fazio, C., Montanaro, L., Graziani, G., Fogliano, V., Munarini, A., Bianchi, F., Belluzzi, A., Bazzoli, F. and Ricciardiello, L. (2014). A combination of eicosapentaenoic acid-free fatty acid, epigallocatechin-3-gallate and proanthocyanidins has a strong effect on mTOR signaling in colorectal cancer cells. Carcinogenesis 35:2314–2320.
   PubMed Web of Science ®Google Scholar
• De Amicis, F., Russo, A., Avena, P., Santoro, M., Vivacqua, A., Bonofiglio, D., Mauro, L., Aquila, S., Tramontano, D., Fuqua, S. A. W. and Ando, S. (2013). In vitro mechanism for downregulation of ER-alpha expression by epigallocatechin gallate in ER+/PR+ human breast cancer cells. Mol. Nutr. Food Res. 57:840–853.
   PubMed Web of Science ®Google Scholar
• De Pace, R. C. C., Liu, X. L., Sun, M., Nie, S. F., Zhang, J., Cai, Q. S., Gao, W. M., Pan, X., Fan, Z. Y. and Wang, S. (2013). Anticancer activities of (-)-epigallocatechin-3-gallate encapsulated nanoliposomes in MCF7 breast cancer cells. J. Liposome Res. 23:187–196.
   PubMed Web of Science ®Google Scholar
• Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, F., Sacchi, A., Blandino, G. and Piaggio, G. (2006). Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10:191–202.
   PubMed Web of Science ®Google Scholar
• Dinarello, C. A. (2006). The paradox of pro-inflammatory cytokines in cancer. Cancer Metast. Rev. 25:307–313.
   PubMed Web of Science ®Google Scholar
• Ding, J., Yao, J., Xue, J. J., Li, R., Bao, B., Jiang, L. P., Zhu, J. J. and He, Z. W. (2015). Tumor-homing cell-penetrating peptide linked to colloidal mesoporous silica encapsulated (-)-epigallocatechin-3-gallate as drug delivery system for breast cancer therapy in vivo. ACS Appl. Mater. Inter. 7:18145–18155.
   PubMed Web of Science ®Google Scholar
• Du, G. J., Wang, C. Z., Qi, L. W., Zhang, Z. Y., Calway, T., He, T. C., Du, W., and Yuan, C. S. (2013). The Synergistic apoptotic interaction of panaxadiol and epigallocatechin gallate in human colorectal cancer cells. Phytother. Res. 27:272–277.
   PubMed Web of Science ®Google Scholar
• Du, G. J., Zhang, Z. Y., Wen, X. D., Yu, C. H., Calway, T., Yuan, C. S. and Wang, C. Z. (2012). Epigallocatechin gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients 4:1679–1691.
   PubMed Web of Science ®Google Scholar
• Duhon, D., Bigelow, R. L. H., Coleman, D. T., Steffan, J. J., Yu, C., Langston, W., Kevil, C. G. and Cardelli, J. A. (2010). The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells. Mol. Carcinogen. 49:739–749.
   PubMed Web of Science ®Google Scholar
• Eom, D. W., Lee, J. H., Kim, Y. J., Hwang, G. S., Kim, S. N., Kwak, J. H., Cheon, G. J., Kim, K. H., Jang, H. J., Ham, J., Kang, K. S. and Yamabe, N. (2015). Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells. Bmb. Rep. 48:461–466.
   PubMed Web of Science ®Google Scholar
• Feitelson, M. A., Arzumanyan, A., Kulathinal, R. J., Blain, S. W., Holcombe, R. F., Mahajna, J., Marino, M., Martinez-Chantar, M. L., Nawroth, R., Sanchez-Garcia, I., Sharma, D., Saxena, N. K., Singh, N., Vlachostergios, P. J., Guo, S. C., Honoki, K., Fujii, H., Georgakilas, A. G., Bilsland, A., Amedei, A., Niccolai, E., Amin, A., Ashraf, S. S., Boosani, C. S., Guha, G., Ciriolo, M. R., Aquilano, K., Chen, S., Mohammed, S. I., Azmi, A. S., Bhakta, D., Halicka, D., Keith, W. N. and Nowsheen, S. (2015). Sustained proliferation in cancer: mechanisms and novel therapeutic targets. Semin. Cancer Biol. 35:S25–S54.
   PubMed Web of Science ®Google Scholar
• Fu, H. J., He, J., Mei, F., Zhang, Q., Hara, Y., Ryota, S., Lubet, R. A., Chen, R., Chen, D. R. and You, M. (2009). Lung cancer inhibitory effect of epigallocatechin-3-gallate is dependent on its presence in a complex mixture (Polyphenon E). Cancer Prev. Res. 2:531–537.
   PubMed Web of Science ®Google Scholar
• Gao, Y. T., Mclaughlin, J. K., Blot, W. J., Ji, B. T., Dai, Q. and Fraumeni, J. F. (1994). Reduced risk of esophageal cancer-associated with green tea consumption. J. Natl. Cancer I. 86:855–858.
   PubMed Web of Science ®Google Scholar
• Hagen, R. M., Chedea, V. S., Mintoff, C. P., Bowler, E., Morse, H. R. and Ladomery, M. R. (2013). Epigallocatechin-3-gallate promotes apoptosis and expression of the caspase 9a splice variant in PC3 prostate cancer cells. Int. J. Oncol. 43:194–200.
   PubMed Web of Science ®Google Scholar
• Hallinan, N., Finn, S., Cuffe, S., Rafee, S., O'Byrne, K. and Gately, K. (2016). Targeting the fibroblast growth factor receptor family in cancer. Cancer Treat. Rev. 46:51–62.
   PubMed Web of Science ®Google Scholar
• Harper, C. E., Patel, B. B., Wang, J., Eltoum, I. A. and Lamartiniere, C. A. (2007). Epigallocatechin-3-gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action. Prostate 67:1576–1589.
   PubMed Web of Science ®Google Scholar
• Hasegawa, S., Koshikawa, N., Momiyama, N., Moriyama, K., Ichikawa, Y., Ishikawa, T., Mitsuhashi, M., Shimada, H. and Miyazaki, K. (1998). Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int. J. Cancer 76:812–816.
   PubMed Web of Science ®Google Scholar
• He, L., Zhang, E. Y., Shi, J. L., Li, X. Y., Zhou, K. Y., Zhang, Q. Z., Le, A. D. and Tang, X. D. (2013). (-)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenesis in non-small cell lung cancer cells by targeting HIF-1 alpha. Cancer Chemoth. Pharm. 71:713–725.
   PubMed Web of Science ®Google Scholar
• Hsieh, D. S., Wang, H., Tan, S. W., Huang, Y. H., Tsai, C. Y., Yeh, M. K. and Wu, C. J. (2011). The treatment of bladder cancer in a mouse model by epigallocatechin-3-gallate-gold nanoparticles. Biomaterials 32:7633–7640.
   PubMed Web of Science ®Google Scholar
• Hu, Q., Chang, X., Yan, R., Rong, C. P., Yang, C., Cheng, S. Y., Gu, X. Q., Yao, H. R., Hou, X. Q., Mo, Y. S., Zhao, L. G., Chen, Y. B., Dinlin, X. X., Wang, Q. and Fang, S. H. (2015). (-)-Epigallocatechin-3-gallate induces cancer cell apoptosis via acetylation of amyloid precursor protein. Med. Oncol. 32:390.
   PubMed Web of Science ®Google Scholar
• Huang, B., Warner, M. and Gustafsson, J. A. (2015). Estrogen receptors in breast carcinogenesis and endocrine therapy. Mol. Cell Endocrinol. 418:240–244.
   PubMed Web of Science ®Google Scholar
• Huang, C. H., Tsai, S. J., Wang, Y. J., Pan, M. H., Kao, J. Y. and Way, T. D. (2009). EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53 positive and negative human hepatoma cells. Mol. Nutr. Food Res. 53:1156–1165.
   PubMed Web of Science ®Google Scholar
• Hwang, Y. S., Park, K. K. and Chung, W. Y. (2013). Epigallocatechin-3 gallate inhibits cancer invasion by repressing functional invadopodia formation in oral squamous cell carcinoma. Eur. J. Pharmacol. 715:286–295.
   PubMed Web of Science ®Google Scholar
• Irimie, A. I., Braicu, C., Zanoaga, O., Pileczki, V., Gherman, C., Berindan-Neagoe, I. and Campian, R. S. (2015). Epigallocatechin-3-gallate suppresses cell proliferation and promotes apoptosis and autophagy in oral cancer SSC-4 cells. Oncotargets Ther. 8:461–470.
   PubMed Web of Science ®Google Scholar
• Iso, H., Date, C., Wakai, K., Fukui, M., Tamakoshi, A. and Grp, J. S. (2006). The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults. Ann. Intern. Med. 144:554–562.
   PubMed Web of Science ®Google Scholar
• Jang, J. Y., Lee, J. K., Jeon, Y. K. and Kim, C. W. (2013). Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization. BMC Cancer 13:421.
   PubMed Web of Science ®Google Scholar
• Jin, H. Y., Gong, W., Zhang, C. X. and Wang, S. M. (2013a). Epigallocatechin gallate inhibits the proliferation of colorectal cancer cells by regulating Notch signaling. Oncotargets Ther. 6:145–152.
   PubMed Web of Science ®Google Scholar
• Jin, L. Y., Li, C., Xu, Y., Wang, L., Liu, J. X., Wang, D. J., Hong, C., Jiang, Z. B., Ma, Y. C., Chen, Q. and Yu, F. L. (2013b). Epigallocatechin gallate promotes p53 accumulation and activity via the inhibition of MDM2-mediated p53 ubiquitination in human lung cancer cells. Oncol. Rep. 29:1983–1990.
   PubMed Web of Science ®Google Scholar
• Kale, A., Gawande, S., Kotwal, S., Netke, S., Roomi, W., Ivanov, V., Niedzwiecki, A. and Rath, M. (2010). Studies on the effects of oral administration of nutrient mixture, quercetin and red onions on the bioavailability of epigallocatechin gallate from green tea extract. Phytother. Res. 24:S48–S55.
   PubMed Web of Science ®Google Scholar
• Khan, M. A., Hussain, A., Sundaram, M. K., Alalami, U., Gunasekera, D., Ramesh, L., Hamza, A. and Quraishi, U. (2015). (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells. Oncol. Rep. 33:1976–1984.
   PubMed Web of Science ®Google Scholar
• Khan, N., Afaq, F., Saleem, M., Ahmad, N. and Mukhtar, H. (2006). Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res. 66:2500–2505.
   PubMed Web of Science ®Google Scholar
• Kim, J., Zhang, X., Rieger-Christ, K. M., Summerhayes, I. C., Wazer, D. E., Paulson, K. E. and Yee, A. S. (2006). Suppression of Wnt signaling by the green tea compound (-)-epigallocatechin 3-gallate (EGCG) in invasive breast cancer cells. Requirement of the transcriptional repressor HBP1. J. Biol. Chem. 281:10865–10875.
   PubMed Web of Science ®Google Scholar
• Kim, K. C. and Lee, C. (2014). Reversal of cisplatin resistance by epigallocatechin gallate is mediated by downregulation of Axl and Tyro 3 expression in human lung cancer cells. Korean J. Physiol. Ph.a 18:61–66.
   PubMed Web of Science ®Google Scholar
• Kim, M., Murakami, A., Kawabata, K. and Ohigashi, H. (2005). (-)-epigallocatechin-3-gallate promotes pro-matrix metalloproteinase-7 production via activation of the JNK1/2 pathway in HT-29 human colorectal cancer cells. Carcinogenesis 26:1553–1562.
   PubMed Web of Science ®Google Scholar
• Kim, M., Murakami, A. and Ohigashi, H. (2007). Modifying effects of dietary factors on (-)-epigallocatechin-3-gallate-induced pro-matrix metalloproteinase-7 production in HT-29 human colorectal cancer cells. Biosci. Biotechnol. Biochem. 71:2442–2450.
   PubMed Web of Science ®Google Scholar
• Koh, Y. W., Choia, E. C., Kang, S. U., Hwang, H. S., Lee, M. H., Pyun, J., Park, R., Lee, Y. and Kim, C. H. (2011). Green tea (-)-epigallocatechin-3-gallate inhibits HGF-induced progression in oral cavity cancer through suppression of HGF/c-Met. J. Nutr. Biochem. 22:1074–1083.
   PubMed Web of Science ®Google Scholar
• Kohri, T., Matsumoto, N., Yamakawa, M., Suzuki, M., Nanjo, F., Hara, Y. and Oku, N. (2001a). Metabolic fate of (-)-[4-H-3]epigallocatechin gallate in rats after oral administration. J. Agric. Food Chem. 49:4102–4112.
   PubMed Web of Science ®Google Scholar
• Kohri, T., Nanjo, F., Suziki, M., Seto, R., Matsumoto, N., Yamakawa, M., Hojo, H., Hara, Y., Desai, D., Amin, S., Conaway, C. C. and Chung, F. L. (2001b). Synthesis of (-)-[4-H-3]epigallocatechin gallate and its metabolic fate in rats after intravenous administration. J. Agric. Food Chem. 49:1042–1048.
   PubMed Web of Science ®Google Scholar
• Kostin, S. F., McDonald, D. E. and McFadden, D. W. (2012). Inhibitory effects of (-)-epigallocatechin-3-gallate and pterostilbene on pancreatic cancer growth in vitro. J. Surg. Res. 177:255–262.
   PubMed Web of Science ®Google Scholar
• Kurahashi, N., Sasazuki, S., Iwasaki, M., Inoue, M., Tsugane, S. and Grp, J. S. (2008). Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am. J. Epidemiol. 167:71–77.
   PubMed Web of Science ®Google Scholar
• Kuriyama, S., Shimazu, T., Ohmori, K., Kikuchi, N., Nakaya, N., Nishino, Y., Tsubono, Y. and Tsuji, I. (2006). Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan—the Ohsaki study. J. Am. Med. Assoc. 296:1255–1265.
   PubMed Web of Science ®Google Scholar
• Lambert, J. D., Hong, J., Kim, D. H., Mishin, V. M. and Yang, C. S. (2004). Piperine enhances the bioavailability of the tea polyphenol (-)-epigallocatechin-3-gallate in mice. J. Nutr. 134:1948–1952.
   PubMed Web of Science ®Google Scholar
• Lambert, J. D., Kwon, S. J., Ju, J., Bose, M., Lee, M. J., Hong, J., Hao, X. and Yang, C. S. (2008a). Effect of genistein on the bioavailability and intestinal cancer chemopreventive activity of (-)-epigallocatechin-3-gallate. Carcinogenesis 29:2019–2024.
   PubMed Web of Science ®Google Scholar
• Lambert, J. D., Lee, M. J., Diamond, L., Ju, J. Y., Bose, M., Newmark, H. L. and Yang, C. S. (2006). Dose-dependent levels of epigallocatechin-3-gallate in human colon cancer cells and mouse plasma and tissues. Drug Metab. Dispos. 34:8–11.
   PubMed Web of Science ®Google Scholar
• Lambert, J. D., Sang, S. M. and Yang, C. S. (2008b). N-acetylcysteine enhances the lung cancer inhibitory effect of epigallocatechin-3-gallate and forms a new adduct. Free Radical Bio. Med. 44:1069–1074.
   PubMed Web of Science ®Google Scholar
• Lang, F., Alevizopoulos, K. and Stournaras, C. (2013). Targeting membrane androgen receptors in tumors. Expert Opin. Ther. Tar. 17:951–963.
   PubMed Web of Science ®Google Scholar
• Larsen, C. A. and Dashwood, R. H. (2010). (-)-Epigallocatechin-3-gallate inhibits Met signaling, proliferation, and invasiveness in human colon cancer cells. Arch. Biochem. Biophys. 501:52–57.
   PubMed Web of Science ®Google Scholar
• Lee, S. C., Chan, W. K., Lee, T. W., Lam, W. H., Wang, X., Chan, T. H. and Wong, Y. C. (2008). Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo. Nutr. Cancer 60:483–491.
   PubMed Web of Science ®Google Scholar
• Lee, S. H., Nam, H. J., Kang, H. J., Kwon, H. W. and Lim, Y. C. (2013). Epigallocatechin-3-gallate attenuates head and neck cancer stem cell traits through suppression of Notch pathway. Eur. J. Cancer 49:3210–3218.
   PubMed Web of Science ®Google Scholar
• Lee, W. J., Shim, J. Y. and Zhu, B. T. (2005). Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol. Pharmacol. 68:1018–1030.
   PubMed Web of Science ®Google Scholar
• Li, G. X., Chen, Y. K., Hou, Z., Xiao, H., Jin, H., Lu, G., Lee, M. J., Liu, B., Guan, F., Yang, Z., Yu, A. and Yang, C. S. (2010). Pro-oxidative activities and dose-response relationship of (-)-epigallocatechin-3-gallate in the inhibition of lung cancer cell growth: a comparative study in vivo and in vitro. Carcinogenesis 31:902–910.
   PubMed Web of Science ®Google Scholar
• Li, X. Y., Feng, Y., Liu, J. H., Feng, X. W., Zhou, K. Y. and Tang, X. D. (2013). Epigallocatechin-3-gallate inhibits IGF-1-stimulated lung cancer angiogenesis through downregulation of HIF-l alpha and VEGF expression. J. Nutrigenet. Nutrige. 6:169–178.
   PubMed Web of Science ®Google Scholar
• Li, Y. J., Wu, S. L., Lu, S. M., Chen, F., Guo, Y., Gan, S. M., Shi, Y. L., Liu, S. and Li, S. L. (2015). (-)-Epigallocatechin-3-gallate inhibits nasopharyngeal cancer stem cell self-renewal and migration and reverses the epithelial-mesenchymal transition via NF-kappaB p65 inactivation. Tumour Biol. 36:2747–2761.
   PubMed Web of Science ®Google Scholar
• Li, Y. Y., Zhang, T., Jiang, Y. Q., Lee, H. F., Schwartz, S. J. and Sun, D. X. (2009). (-)-Epigallocatechin-3-gallate inhibits Hsp90 function by impairing Hsp90 association with cochaperones in pancreatic cancer cell line Mia Paca-2. Mol. Pharmaceut. 6:1152–1159.
   PubMed Web of Science ®Google Scholar
• Lin, C. H., Chao, L. K., Hung, P. H. and Chen, Y. J. (2014). EGCG inhibits the growth and tumorigenicity of nasopharyngeal tumor-initiating cells through attenuation of STAT3 activation. Int. J. Clin. Exp. Patho. 7:2372–2381.
   PubMed Web of Science ®Google Scholar
• Li-Weber, M. (2013). Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett. 332:304–312.
   PubMed Web of Science ®Google Scholar
• Luo, T., Wang, J., Yin, Y. C., Hua, H., Jing, J., Sun, X. M., Li, M. J., Zhang, Y. and Jiang, Y. F. (2010). (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Res. 12:R8.
   PubMed Web of Science ®Google Scholar
• Ma, J., Shi, M., Li, G. M., Wang, N., Wei, J., Wang, T., Ma, J. L. and Wang, Y. G. (2013). Regulation of Id1 expression by epigallocatechin-3-gallate and its effect on the proliferation and apoptosis of poorly differentiated AGS gastric cancer cells. Int. J. Oncol. 43:1052–1058.
   PubMed Web of Science ®Google Scholar
• Ma, Y. C., Li, C., Gao, F., Xu, Y., Jiang, Z. B., Liu, J. X. and Jin, L. Y. (2014). Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the EGFR signaling pathway. Oncol. Rep. 31:1343–1349.
   PubMed Web of Science ®Google Scholar
• Mann, J. R., Backlund, M. G. and DuBois, R. N. (2005). Mechanisms of disease: inflammatory mediators and cancer prevention. Nat. Clin. Pract. Oncol. 2:202–210.
   PubMedGoogle Scholar
• Marotta, L. L. C., Almendro, V., Marusyk, A., Shipitsin, M., Schemme, J., Walker, S. R., Bloushtain-Qimron, N., Kim, J. J., Choudhury, S. A., Maruyama, R., Wu, Z., Gonen, M., Mulvey, L. A., Bessarabova, M. O., Huh, S. J., Silver, S. J., Kim, S. Y., Park, S. Y., Lee, H. E., Anderson, K. S., Richardson, A. L., Nikolskaya, T., Nikolsky, Y., Liu, X. S., Root, D. E., Hahn, W. C., Frank, D. A. and Polyak, K. (2011). The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 121:2723–2735.
   PubMed Web of Science ®Google Scholar
• Maruyama, T., Murata, S., Nakayama, K., Sano, N., Ogawa, K., Nowatari, T., Tamura, T., Nozaki, R., Fukunaga, K. and Ohkohchi, N. (2014). (-)-Epigallocatechin-3-gallate suppresses liver metastasis of human colorectal cancer. Oncol. Rep. 31:625–633.
   PubMed Web of Science ®Google Scholar
• Masuda, M., Suzui, M. and Weinstein, I. B. (2001). Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin. Cancer Res. 7:4220–4229.
   PubMed Web of Science ®Google Scholar
• Mayr, C., Wagner, A., Neureiter, D., Pichler, M., Jakab, M., Illig, R., Berr, F. and Kiesslich, T. (2015). The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells. BMC Complem. Altern. M. 15:194.
   PubMed Web of Science ®Google Scholar
• McLaughlin, N., Annabi, B., Bouzeghrane, M., Temme, A., Bahary, J. P., Moumdjian, R. and Beliveau, R. (2006). The Survivin-mediated radioresistant phenotype of glioblastomas is regulated by RhoA and inhibited by the green tea polyphenol (-)-epigallocatechin-3-gallate. Brain Res. 1071:1–9.
   PubMed Web of Science ®Google Scholar
• Meeran, S. M., Patel, S. N., Chan, T. H. and Tollefsbol, T. O. (2011). A novel prodrug of epigallocatechin-3-gallate: differential epigenetic hTERT repression in human breast cancer cells. Cancer Prev. Res. 4:1243–1254.
   PubMed Web of Science ®Google Scholar
• Min, N. Y., Kim, J. H., Choi, J. H., Liang, W., Ko, Y. J., Rhee, S., Bang, H., Ham, S. W., Park, A. J. and Lee, K. H. (2012). Selective death of cancer cells by preferential induction of reactive oxygen species in response to (-)-epigallocatechin-3-gallate. Biochem. Bioph. Res. Co. 421:91–97.
   PubMed Web of Science ®Google Scholar
• Mineva, N. D., Paulson, K. E., Naber, S. P., Yee, A. S. and Sonenshein, G. E. (2013). Epigallocatechin-3-gallate inhibits stem-like inflammatory breast cancer cells. PLoS One 8:e73464.
   PubMed Web of Science ®Google Scholar
• Montenegro, M. F., Sanchez-del-Campo, L., Fernandez-Perez, M. P., Saez-Ayala, M., Cabezas-Herrera, J. and Rodriguez-Lopez, J. N. (2015). Targeting the epigenetic machinery of cancer cells. Oncogene 34:135–143.
   PubMed Web of Science ®Google Scholar
• Moreira, L., Araujo, I., Costa, T., Correia-Branco, A., Faria, A., Martel, F. and Keating, E. (2013). Quercetin and epigallocatechin gallate inhibit glucose uptake and metabolism by breast cancer cells by an estrogen receptor-independent mechanism. Exp. Cell Res. 319:1784–1795.
   PubMed Web of Science ®Google Scholar
• Moseley, V. R., Morris, J., Knackstedt, R. W. and Wargovich, M. J. (2013). Green tea polyphenol epigallocatechin 3-gallate, contributes to the degradation of DNMT3A and HDAC3 in HCT 116 human colon cancer cells. Anticancer Res. 33:5325–5333.
   PubMed Web of Science ®Google Scholar
• Moses, M. A., Henry, E. C., Ricke, W. A. and Gasiewicz, T. A. (2015). The heat shock protein 90 Inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model. Cancer Prev. Res. 8:249–257.
   PubMed Web of Science ®Google Scholar
• Munn, D. H. and Mellor, A. L. (2007). Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117:1147–1154.
   PubMed Web of Science ®Google Scholar
• Nair, S., Barve, A., Khor, T. O., Shen, G. X., Lin, W., Chan, J. Y., Cai, L. and Kong, A. N. (2010). Regulation of Nrf2-and AP-1-mediated gene expression by epigallocatechin-3-gallate and sulforaphane in prostate of Nrf2-knockout or C57BL/6J mice and PC-3 AP-1 human prostate cancer cells. Acta Pharmacol. Sin. 31:1223–1240.
   PubMed Web of Science ®Google Scholar
• Nakagawa, K. and Miyazawa, T. (1997). Chemiluminescence-high-performance liquid chromatographic determination of tea catechin, (-)-epigallocatechin 3-gallate, at picomole levels in rat and human plasma. Anal. Biochem. 248:41–49.
   PubMed Web of Science ®Google Scholar
• Nakagawa, K., Nakayama, K., Nakamura, M., Sookwong, P., Tsuduki, T., Niino, H., Kimura, F. and Miyazawa, T. (2009). Effects of co-administration of tea epigallocatechin-3-gallate (EGCG) and caffeine on absorption and metabolism of EGCG in humans. Biosci. Biotechnol. Biochem. 73:2014–2017.
   PubMed Web of Science ®Google Scholar
• Nishimura, N., Hartomo, T. B., Pham, T. V., Lee, M. J., Yamamoto, T., Morikawa, S., Hasegawa, D., Takeda, H., Kawasaki, K., Kosaka, Y., Yamamoto, N., Kubokawa, I., Mori, T., Yanai, T., Hayakawa, A., Takeshima, Y., Iijima, K., Matsuo, M. and Nishio, H. (2012). Epigallocatechin gallate inhibits sphere formation of neuroblastoma BE(2)-C cells. Environ. Health Prev. Med. 17:246–251.
   PubMedGoogle Scholar
• Nowell, S. A., Massengill, J. S., Williams, S., Radominska-Pandya, A., Tephly, T. R., Cheng, Z. Q., Strassburg, C. P., Tukey, R. H., MacLeod, S. L., Lang, N. P. and Kadlubar, F. F. (1999). Glucuronidation of 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine by human microsomal UDP-glucuronosyltransferases: identification of specific UGT1A family isoforms involved. Carcinogenesis 20:1107–1114.
   PubMed Web of Science ®Google Scholar
• Ogawa, K., Hara, T., Shimizu, M., Nagano, J., Ohno, T., Hoshi, M., Ito, H., Tsurumi, H., Saito, K., Seishima, M. and Moriwaki, H. (2012). (-)-Epigallocatechin gallate inhibits the expression of indoleamine 2,3-dioxygenase in human colorectal cancer cells. Oncol. Lett. 4:546–550.
   PubMed Web of Science ®Google Scholar
• Onoda, C., Kuribayashi, K., Nirasawa, S., Tsuji, N., Tanaka, M., Kobayashi, D. and Watanabe, N. (2011). (-)-Epigallocatechin-3-gallate induces apoptosis in gastric cancer cell lines by down-regulating survivin expression. Int. J. Oncol. 38:1403–1408.
   PubMed Web of Science ®Google Scholar
• Osanai, K., Landis-Piwowar, K. R., Dou, Q. P. and Chan, T. H. (2007). A para-amino substituent on the D-ring of green tea polyphenol epigallocatechin-3-gallate as a novel proteasome inhibitor and cancer cell apoptosis inducer. Bioorgan. Med. Chem. 15:5076–5082.
   PubMed Web of Science ®Google Scholar
• Pan, X., Zhao, B., Song, Z., Han, S. and Wang, M. (2016). Estrogen receptor-alpha36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells. J. Pharmacol. Sci. 130:85–93.
   PubMed Web of Science ®Google Scholar
• Papi, A., Farabegoli, F., Iori, R., Orlandi, M., De Nicola, G. R., Bagatta, M., Angelino, D., Gennari, L. and Ninfali, P. (2013). Vitexin-2–0-xyloside, raphasatin and (-)-epigallocatechin-3-gallate synergistically affect cell growth and apoptosis of colon cancer cells. Food Chem. 138:1521–1530.
   PubMed Web of Science ®Google Scholar
• Pianetti, S., Guo, S. Q., Kavanagh, K. T. and Sonenshein, G. E. (2002). Green tea polyphenol epigallocatechin-3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res. 62:652–655.
   PubMed Web of Science ®Google Scholar
• Pollard, C., Liu, B., Zhou, L. and Percival, S. S. (2012). (-)-Epigallocatechin-3-gallate sensitizes human promyelocytic HL-60 cells to x-ray irradiation and alters expression of pro-apoptotic genes. FASEB J. 26.
   Web of Science ®Google Scholar
• Qiao, Y., Cao, J., Xie, L. and Shi, X. (2009). Cell growth inhibition and gene expression regulation by (-)-epigallocatechin-3-gallate in human cervical cancer cells. Arch. Pharm. Res. 32:1309–1315.
   PubMed Web of Science ®Google Scholar
• Qin, J., Wang, Y. B., Bai, Y., Yang, K., Mao, Q. Q., Lin, Y. W., Kong, D. B., Zheng, X. Y. and Xie, L. P. (2012). Epigallocatechin-3-gallate inhibits bladder cancer cell invasion via suppression of NF-kappa B-mediated matrix metalloproteinase-9 expression. Mol. Med. Rep. 6:1040–1044.
   PubMed Web of Science ®Google Scholar
• Rahman, A. A., Makpol, S., Jamal, R., Harun, R., Mokhtar, N. and Ngah, W. Z. W. (2014). Tocotrienol-rich fraction, [6]-gingerol and epigallocatechin gallate inhibit proliferation and induce apoptosis of glioma cancer cells. Molecules 19:14528–14541.
   PubMed Web of Science ®Google Scholar
• Ranzato, E., Magnelli, V., Martinotti, S., Waheed, Z., Cain, S. M., Snutch, T. P., Marchetti, C. and Burlando, B. (2014). Epigallocatechin-3-gallate elicits Ca2+ spike in MCF-7 breast cancer cells: essential role of Cav3.2 channels. Cell Calcium. 56:285–295.
   PubMed Web of Science ®Google Scholar
• Rao, S. D. and Pagidas, K. (2010). Epigallocatechin-3-gallate, a natural polyphenol, inhibits cell proliferation and induces apoptosis in human ovarian cancer cells. Anticancer Res. 30:2519–2523.
   PubMed Web of Science ®Google Scholar
• Relat, J., Blancafort, A., Oliveras, G., Cufi, S., Haro, D., Marrero, P. F. and Puig, T. (2012). Different fatty acid metabolism effects of (-)-epigallocatechin-3-gallate and C75 in adenocarcinoma lung cancer. BMC Cancer 12:280.
   PubMed Web of Science ®Google Scholar
• Rocha, S., Generalov, R., Pereira, M. D., Peres, I., Juzenas, P. and Coelho, M. A. N. (2011). Epigallocatechin gallate-loaded polysaccharide nanoparticles for prostate cancer chemoprevention. Nanomedicine 6:79–87.
   PubMed Web of Science ®Google Scholar
• Roomi, M. W., Ivanov, V., Kalinovsky, T., Niedzwiecki, A. and Rath, M. (2004). Anti-tumor effect of ascorbic acid, lysine, proline, arginine, and epigallocatechin gallate on prostate cancer cell lines PC-3, LNCaP, and DU145. Res. Commun. Mol. Pathol. Pharmacol. 115–116:251–264.
   PubMedGoogle Scholar
• Rudolph-Owen, L. A., Chan, R., Muller, W. J. and Matrisian, L. M. (1998). The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res. 58:5500–5506.
   PubMed Web of Science ®Google Scholar
• Russell, P. J., Bennett, S. and Stricker, P. (1998). Growth factor involvement in progression of prostate cancer. Clin. Chem. 44:705–723.
   PubMed Web of Science ®Google Scholar
• Sadava, D., Whitlock, E. and Kane, S. E. (2007). The green tea polyphenol, epigallocatechin-3-gallate inhibits telomerase and induces apoptosis in drug-resistant lung cancer cells. Biochem. Bioph. Re.s Co. 360:233–237.
   PubMed Web of Science ®Google Scholar
• Sakamoto, Y., Terashita, N., Muraguchi, T., Fukusato, T. and Kubota, S. (2013). Effects of epigallocatechin-3-gallate (EGCG) on A549 lung cancer tumor growth and angiogenesis. Biosci. Biotech. Bioch. 77:1799–1803.
   PubMed Web of Science ®Google Scholar
• Saldanha, S. N., Kala, R. and Tollefsbol, T. O. (2014). Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate. Exp. Cell Res. 324:40–53.
   PubMed Web of Science ®Google Scholar
• Saldanha, S. N. and Tollefsbol, T. O. (2012). The role of nutraceuticals in chemoprevention and chemotherapy and their clinical outcomes. J. Oncol. 2012:192464.
   PubMedGoogle Scholar
• Schwarze, S. R., Lin, E. W., Christian, P. A., Gayheart, D. T. and Kyprianou, N. (2008). Intracellular death platform steps-in: targeting prostate tumors via endoplasmic reticulum (ER) apoptosis. Prostate 68:1615–1623.
   PubMed Web of Science ®Google Scholar
• Seeram, N. P., Henning, S. M., Niu, Y. T., Lee, R., Scheuller, H. S. and Heber, D. (2006). Catechin and caffeine content of green tea dietary supplements and correlation with antioxidant capacity. J. Agric. Food Chem. 54:1599–1603.
   PubMed Web of Science ®Google Scholar
• Semenza, G. L. (2012). Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 33:207–214.
   PubMed Web of Science ®Google Scholar
• Sen, T. and Chatterjee, A. (2011). Epigallocatechin-3-gallate (EGCG) downregulates EGF-induced MMP-9 in breast cancer cells: involvement of integrin receptor alpha 5 beta 1 in the process. Eur. J. Nutr. 50:465–478.
   PubMed Web of Science ®Google Scholar
• Sen, T., Dutta, A. and Chatterjee, A. (2010). Epigallocatechin-3-gallate (EGCG) downregulates gelatinase-B (MMP-9) by involvement of FAK/ERK/NF kappa B and AP-1 in the human breast cancer cell line MDA-MB-231. Anticancer Drugs 21:632–644.
   PubMed Web of Science ®Google Scholar
• Sen, T., Moulik, S., Dutta, A., Choudhury, P. R., Banerji, A., Das, S., Roy, M. and Chatterjee, A. (2009). Multifunctional effect of epigallocatechin-3-gallate (EGCG) in downregulation of gelatinase-A (MMP-2) in human breast cancer cell line MCF-7. Life Sci. 84:194–204.
   PubMed Web of Science ®Google Scholar
• Shankar, S., Suthakar, G. and Srivastava, R. K. (2007). Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer. Front. Biosci. 12:5039–5051.
   PubMed Web of Science ®Google Scholar
• Sharma, C., Nusri, Q. E. A., Begum, S., Javed, E., Rizvi, T. A. and Hussain, A. (2012). (-)-Epigallocatechin-3-gallate induces apoptosis and inhibits invasion and migration of human cervical cancer cells. Asian Pac. J. Cancer P. 13:4815–4822.
   PubMedGoogle Scholar
• Shi, J. L., Liu, F., Zhang, W. Z., Liu, X., Lin, B. H. and Tang, X. D. (2015). Epigallocatechin-3-gallate inhibits nicotine-induced migration and invasion by the suppression of angiogenesis and epithelial-mesenchymal transition in non-small cell lung cancer cells. Oncol. Rep. 33:2972–2980.
   PubMed Web of Science ®Google Scholar
• Shimizu, M., Shirakami, Y., Sakai, H., Yasuda, Y., Kubota, M., Adachi, S., Tsurumi, H., Hara, Y. and Moriwaki, H. (2010). (-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells. Chem. Biol. Interact. 185:247–252.
   PubMed Web of Science ®Google Scholar
• Siddiqui, I. A., Adhami, V. M., Bharali, D. J., Hafeez, B. B., Asim, M., Khwaja, S. I., Ahmad, N., Cui, H. D., Mousa, S. A. and Mukhtar, H. (2009). Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res. 69:1712–1716.
   PubMed Web of Science ®Google Scholar
• Singh, T. and Katiyar, S. K. (2013). Green tea polyphenol, (-)-epigallocatechin-3-gallate, induces toxicity in human skin cancer cells by targeting beta-catenin signaling. Toxicol. Appl. Pharmacol. 273:418–424.
   PubMed Web of Science ®Google Scholar
• Somers-Edgar, T. J., Scandlyn, M. J., Stuart, E. C., Le Nedelec, M. J., Valentine, S. P. and Rosengren, R. J. (2008). The combination of epigallocatechin gallate and curcumin suppresses ER alpha-breast cancer cell growth in vitro and in vivo. Int. J. Cancer 122:1966–1971.
   PubMed Web of Science ®Google Scholar
• Sonoda, J. I., Ikeda, R., Baba, Y., Narumi, K., Kawachi, A., Tomishige, E., Nishihara, K., Takeda, Y., Yamada, K., Sato, K. and Motoya, T. (2014). Green tea catechin, epigallocatechin-3-gallate, attenuates the cell viability of human non-small-cell lung cancer A549 cells via reducing Bcl-xL expression. Exp. Ther. Med. 8:59–63.
   PubMed Web of Science ®Google Scholar
• Stearns, M. E., Amatangelo, M. D., Varma, D., Sell, C. and Goodyear, S. M. (2010). Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies inhibition of metastatic tumor growth in severe combined immunodeficiency mice. Am. J. Pathol. 177:3169–3179.
   PubMed Web of Science ®Google Scholar
• Suzuki, A., Hayashida, M., Ito, T., Kawano, H., Nakano, T., Miura, M., Akahane, K. and Shiraki, K. (2000). Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/Cyclin E complex activation. Oncogene 19:3225–3234.
   PubMed Web of Science ®Google Scholar
• Takagaki, A. and Nanjo, F. (2010). Metabolism of (-)-epigallocatechin gallate by rat intestinal flora. J. Agric. Food Chem. 58:1313–1321.
   PubMed Web of Science ®Google Scholar
• Takahashi, A., Watanabe, T., Mondal, A., Suzuki, K., Kurusu-Kanno, M., Li, Z. H., Yamazaki, T., Fujiki, H. and Suganuma, M. (2014). Mechanism-based inhibition of cancer metastasis with (-)-epigallocatechin gallate. Biochem. Bioph. Res. Co. 443:1–6.
   PubMed Web of Science ®Google Scholar
• Takebe, N., Harris, P. J., Warren, R. Q. and Ivy, S. P. (2011). Targeting cancer stem cells by inhibiting Wnt, notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 8:97–106.
   PubMed Web of Science ®Google Scholar
• Tanaka, T., Ishii, T., Mizuno, D., Mori, T., Yamaji, R., Nakamura, Y., Kumazawa, S., Nakayama, T. and Akagawa, M. (2011). (-)-Epigallocatechin-3-gallate suppresses growth of AZ521 human gastric cancer cells by targeting the DEAD-box RNA helicase p68. Free Radic. Biol. Med. 50:1324–1335.
   PubMed Web of Science ®Google Scholar
• Tang, S. N., Singh, C., Nall, D., Meeker, D., Shankar, S. and Srivastava, R. K. (2010). The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J. Mol. Signal. 5:14.
   PubMedGoogle Scholar
• Tang, Y., Zhao, D. Y., Elliott, S., Zhao, W. Q., Curiel, T. J., Beckman, B. S. and Burow, M. E. (2007). Epigallocatechin-3 gallate induces growth inhibition and apoptosis in human breast cancer cells through survivin suppression. Int. J. Oncol. 31:705–711.
   PubMed Web of Science ®Google Scholar
• Thangapazham, R. L., Passi, N. and Maheshwari, R. K. (2007). Green tea polyphenol and epigallocatechin gallate induce apoptosis and inhibit invasion in human breast cancer cells. Cancer Biol. Ther. 6:1938–1943.
   PubMed Web of Science ®Google Scholar
• Thomas, R. and Kim, M. H. (2005). Epigallocatechin gallate inhibits HIF-1 alpha degradation in prostate cancer cells. Biochem. Bioph. Res. Co. 334:543–548.
   PubMed Web of Science ®Google Scholar
• Tipoe, G. L., Leung, T. M., Liong, E. C., Lau, T. Y. H., Fung, M. L. and Nanji, A. A. (2010). Epigallocatechin-3-gallate (EGCG) reduces liver inflammation, oxidative stress and fibrosis in carbon tetrachloride (CCl4)-induced liver injury in mice. Toxicology 273:45–52.
   PubMed Web of Science ®Google Scholar
• Toden, S., Tran, H. M., Tovar-Camargo, O. A., Okugawa, Y. and Goel, A. (2016). Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer. Oncotarget 7:16158–16171.
   PubMed Web of Science ®Google Scholar
• Tu, S. H., Ku, C. Y., Ho, C. T., Chen, C. S., Huang, C. S., Lee, C. H., Chen, L. C., Pan, M. H., Chang, H. W., Chang, C. H., Chang, Y. J., Wei, P. L., Wu, C. H. and Ho, Y. S. (2011). Tea polyphenol (-)-epigallocatechin-3-gallate inhibits nicotine- and estrogen-induced alpha 9-nicotinic acetylcholine receptor upregulation in human breast cancer cells. Mol. Nutr. Food Res. 55:455–466.
   PubMed Web of Science ®Google Scholar
• Umeda, D., Yano, S., Yamada, K. and Tachibana, H. (2008). Involvement of 67-kDa laminin receptor-mediated myosin phosphatase activation in antiproliferative effect of epigallocatechin-3-O-gallate at a physiological concentration on Caco-2 colon cancer cells. Biochem. Bioph. Re.s Co. 371:172–176.
   PubMed Web of Science ®Google Scholar
• van't Slot, G. and Humpf, H. U. (2009). Degradation and metabolism of catechin, epigallocatechin-3-gallate (EGCG), and related compounds by the intestinal microbiota in the pig cecum model. J. Agric. Food Chem. 57:8041–8048.
   PubMed Web of Science ®Google Scholar
• Wagner, H. (2011). Synergy research: approaching a new generation of phytopharmaceuticals. Fitoterapia 82:34–37.
   PubMed Web of Science ®Google Scholar
• Wang, H., Bian, S. J. and Yang, C. S. (2011). Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1 alpha. Carcinogenesis 32:1881–1889.
   PubMed Web of Science ®Google Scholar
• Wang, P., Heber, D. and Henning, S. M. (2012). Quercetin increased the antiproliferative activity of green tea polyphenol (-)-epigallocatechin gallate in prostate cancer cells. Nutr. Cancer 64:580–587.
   PubMed Web of Science ®Google Scholar
• Wang, S. I. and Mukhtar, H. (2002). Gene expression profile in human prostate LNCaP cancer cells by (-) epigallocatechin-3-gallate. Cancer Lett. 182:43–51.
   PubMed Web of Science ®Google Scholar
• Wang, S. P., Chen, R. E., Zhong, Z. F., Shi, Z., Chen, M. W. and Wang, Y. T. (2014). Epigallocatechin-3-gallate potentiates the effect of curcumin in inducing growth inhibition and apoptosis of resistant breast cancer cells. Am. J. Chinese Med. 42:1279–1300.
   PubMed Web of Science ®Google Scholar
• Wei, D. Z., Yang, J. Y., Liu, J. W. and Tong, W. Y. (2003). Inhibition of liver cancer cell proliferation and migration by a combination of (-)-epigallocatechin-3-gallate and ascorbic acid. J. Chemother. 15:591–595.
   PubMed Web of Science ®Google Scholar
• Westermarck, J. and Kahari, V. M. (1999). Regulation of matrix metalloproteinase expression in turner invasion. FASEB J. 13:781–792.
   PubMed Web of Science ®Google Scholar
• Wolfram, S., Raederstorff, D., Preller, M., Wang, Y., Teixeira, S. R., Riegger, C. and Weber, P. (2006). Epigallocatechin gallate supplementation alleviates diabetes in rodents. J. Nutr. 136:2512–2518.
   PubMed Web of Science ®Google Scholar
• Wu, H. J., Xin, Y., Xiao, Y. P. and Zhao, J. (2012a). Low-dose docetaxel combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts. Cancer Biother. Radio. 27:204–209.
   PubMed Web of Science ®Google Scholar
• Wu, H. J., Xin, Y., Xu, C. A. and Xiao, Y. P. (2012b). Capecitabine combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts. Exp. Ther. Med. 3:650–654.
   PubMed Web of Science ®Google Scholar
• Wu, P. P., Kuo, S. C., Huang, W. W., Yang, J. S., Lai, K. C., Chen, H. J., Lin, K. L., Chiu, Y. J., Huang, L. J. and Chung, J. G. (2009). (-)-Epigallocatechin gallate induced apoptosis in human adrenal cancer NCI-H295 cells through caspase-dependent and caspase-independent pathway. Anticancer Res. 29:1435–1442.
   PubMed Web of Science ®Google Scholar
• Wu, X. Q., Huang, C., He, X., Tian, Y. Y., Zhou, D. X., He, Y., Liu, X. H. and Li, J. (2013). Feedback regulation of telomerase reverse transcriptase: new insight into the evolving field of telomerase in cancer. Cell Signal. 25:2462–2468.
   PubMed Web of Science ®Google Scholar
• Wubetu, G. Y., Shimada, M., Morine, Y., Ikemoto, T., Ishikawa, D., Iwahashi, S., Yamada, S., Saito, Y., Arakawa, Y. and Imura, S. (2016). Epigallocatechin gallate hinders human hepatoma and colon cancer sphere formation. J. Gastroenterol. Hepatol. 31:256–264.
   PubMed Web of Science ®Google Scholar
• Xia, P. and Xu, X. Y. (2015). PI3K/Akt/mTOR signaling pathway in cancer stem cells: From basic research to clinical application. Am. J. Cancer Res. 5:1602–1609.
   PubMed Web of Science ®Google Scholar
• Yan, C. X., Yang, J. H., Shen, L. and Chen, X. J. (2012). Inhibitory effect of epigallocatechin gallate on ovarian cancer cell proliferation associated with aquaporin 5 expression. Arch. Gynecol. Obstet. 285:459–467.
   PubMed Web of Science ®Google Scholar
• Ye, F., Zhang, G. H., Guan, B. X. and Xu, X. C. (2012). Suppression of esophageal cancer cell growth using curcumin, (-)-epigallocatechin-3-gallate and lovastatin. World J. Gastroenterol. 18,126–135.
   PubMed Web of Science ®Google Scholar
• Yeh, J. E., Toniolo, P. A. and Frank, D. A. (2013). Targeting transcription factors: promising new strategies for cancer therapy. Curr. Opin. Oncol. 25:652–658.
   PubMed Web of Science ®Google Scholar
• Yin, Z. Y., Henry, E. C. and Gasiewicz, T. A. (2009). (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor. Biochemistry 48:336–345.
   PubMed Web of Science ®Google Scholar
• Yuan, J. H., Li, Y. Q. and Yang, X. Y. (2007). Inhibition of epigallocatechin gallate on orthotopic colon cancer by upregulating the Nrf2-UGT1A signal pathway in nude mice. Pharmacology 80:269–278.
   PubMed Web of Science ®Google Scholar
• Zhang, X. B., Min, K. W., Wimalasena, J. and Baek, S. J. (2012a). Cyclin D1 degradation and p21 induction contribute to growth inhibition of colorectal cancer cells induced by epigallocatechin-3-gallate. J. Cancer Res. Clin. 138:2051–2060.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Han, G., Fan, B., Zhou, Y., Zhou, X., Wei, L. and Zhang, J. (2009). Green tea (-)-epigallocatechin-3-gallate down-regulates VASP expression and inhibits breast cancer cell migration and invasion by attenuating Rac1 activity. Eur. J. Pharmacol. 606:172–179.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Wang, S. X., Ma, J. W., Li, H. Y., Ye, J. C., Xie, S. M., Du, B. and Zhong, X. Y. (2015). EGCG inhibits properties of glioma stem-like cells and synergizes with temozolomide through downregulation of P-glycoprotein inhibition. J. Neuro-Oncol. 121:41–52.
   PubMed Web of Science ®Google Scholar
• Zhang, Y., Yang, N. D., Zhou, F., Shen, T., Duan, T., Zhou, J., Shi, Y., Zhu, X. Q. and Shen, H. M. (2012b). (-)-Epigallocatechin-3-gallate induces non-apoptotic cell death in human cancer cells via ROS-mediated lysosomal membrane permeabilization. Plos One 7:e46749.
   PubMed Web of Science ®Google Scholar
• Zhou, D. H., Wang, X. M., Yang, M. M., Shi, X. Y., Huang, W. B. and Feng, Q. (2013). Combination of low concentration of (-)-epigallocatechin gallate (EGCG) and curcumin strongly suppresses the growth of non-small cell lung cancer in vitro and in vivo through causing cell cycle arrest. Int. J. Mo.l Sci. 14:12023–12036.
   PubMed Web of Science ®Google Scholar
• Zhou, F., Zhou, H., Wang, T., Mu, Y., Wu, B., Guo, D. L., Zhang, X. M. and Wu, Y. (2012). Epigallocatechin-3-gallate inhibits proliferation and migration of human colon cancer SW620 cells in vitro. Acta Pharmacol. Sin. 33:120–126.
   PubMed Web of Science ®Google Scholar
• Zhou, Y. D., Kim, Y. P., Li, X. C., Baerson, S. R., Agarwal, A. K., Hodges, T. W., Ferreira, D. and Nagle, D. G. (2004). Hypoxia-inducible factor-1 activation by (-)-epicatechin gallate: potential adverse effects of cancer chemoprevention with high-dose green tea extracts. J. Nat. Prod. 67:2063–2069.
   PubMed Web of Science ®Google Scholar
• Zhu, B. H., Chen, H. Y., Zhan, W. H., Wang, C. Y., Cai, S. R., Wang, Z., Zhang, C. H. and He, Y. L. (2011). (-)-Epigallocatechin-3-gallate inhibits VEGF expression induced by IL-6 via Stat3 in gastric cancer. World J. Gastroenterol. 17:2315–2325.
   PubMed Web of Science ®Google Scholar
• Zhu, B. H., Zhan, W. H., Li, Z. R., Wang, Z., He, Y. L., Peng, J. S., Cai, S. R., Ma, J. P. and Zhang, C. H. (2007). (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. World J. Gastroenterol. 13:1162–1169.
   PubMed Web of Science ®Google Scholar